TD Cowen Forecasts Strong Price Appreciation for Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX) had its target price upped by investment analysts at TD Cowen from $183.00 to $189.00 in a research note issued to investors on Wednesday,MarketScreener reports. The brokerage presently has a “hold” rating on the medical instruments supplier’s stock. TD Cowen’s price target points to a potential upside of 4.86% from the stock’s current price.

Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. reduced their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Jefferies Financial Group lowered their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a research report on Tuesday. Morgan Stanley boosted their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Finally, Citigroup reduced their target price on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $195.46.

Becton, Dickinson and Company Trading Down 0.2%

Shares of BDX opened at $180.25 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.64 and a current ratio of 1.05. The company has a market cap of $51.32 billion, a price-to-earnings ratio of 29.41, a PEG ratio of 1.90 and a beta of 0.25. The stock has a fifty day moving average price of $199.49 and a two-hundred day moving average price of $192.35. Becton, Dickinson and Company has a 52-week low of $162.29 and a 52-week high of $235.34.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. During the same period last year, the company posted $3.43 earnings per share. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 0% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 2,463 shares of company stock valued at $501,530 in the last quarter. Company insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds have recently added to or reduced their stakes in the business. SOA Wealth Advisors LLC. increased its holdings in shares of Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 95 shares in the last quarter. Activest Wealth Management grew its position in shares of Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 97 shares during the period. Imprint Wealth LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. Steph & Co. raised its holdings in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the period. Finally, Bell Investment Advisors Inc raised its holdings in Becton, Dickinson and Company by 474.1% during the 2nd quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Key Headlines Impacting Becton, Dickinson and Company

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD completed its Biosciences & Diagnostics spin‑off and merged that business with Waters, securing roughly $4.0B in proceeds and repositioning BD as a focused medical‑technology company — a strategic long‑term positive for margin/portfolio clarity. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Q1/CY2025 results beat estimates on EPS and revenues and management set FY2026 EPS guidance (12.35–12.65), supporting the argument that core MedTech operations are resilient despite tariff and mix headwinds. BDX Q4 Deep Dive
• Positive Sentiment: BD announced tender offers to repurchase up to $1.6B of outstanding debt, a sign of active liability management that can improve credit profile over time. Tender Offers for Outstanding Debt Securities
• Neutral Sentiment: Barclays initiated coverage with an Overweight rating ($202 PT), indicating some analyst enthusiasm for the re‑focused company despite mixed peer views. Barclays Coverage Note
• Neutral Sentiment: Some firms lowered price targets but maintained Buy/positive ratings (e.g., Citigroup trimmed its PT modestly to $232 while keeping a buy stance), showing a split between valuation trimming and confidence in longer‑term thesis. Citigroup Lowers Price Target
• Negative Sentiment: Several large brokers cut price targets or moved to neutral/equal‑weight (JPMorgan, Wells Fargo among them), and some issued explicitly pessimistic near‑term forecasts — pressure that drove an analyst‑triggered gap down in the stock. JPMorgan Pessimistic Forecast Wells Fargo Pessimistic Forecast Shares Gap Down on Analyst Downgrade

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.